Lattice Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lattice Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,500	Closed	-$219K	–	42
2023 Q1	$219K	Hold	1,500	–	–	0.03%	47
2022 Q4	$239K	Hold	1,500	–	–	0.04%	45
2022 Q3	$200K	Hold	1,500	–	–	0.32%	52
2022 Q2	$231K	Hold	1,500	–	–	0.42%	52
2022 Q1	$251K	Buy	+1,500	New	+$218K	0.36%	59

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lattice Capital Management's JAZZ Position: Q2 2023 in Review

Lattice Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 1,500 shares — an estimated $219K sold.

Lattice Capital Management first reported a position in JAZZ in Q1 2022 and held it in 5 quarters. The position peaked at $251K in Q1 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Lattice Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Lattice Capital Management sold 1,500 Jazz Pharmaceuticals shares in Q2 2023, an estimated $219K.
Lattice Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Lattice Capital Management's Jazz Pharmaceuticals position peaked at $251K in Q1 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Lattice Capital Management's 13F filing for Q2 2023, filed 28 Jul 2023.